Geratal, April 7, 2022: Geratherm Medical AG (ISIN: DE0005495626) had a stable sales trend in 2021 after the record year 2020. The result was burdened by the one-off expenses of the discontinuation of the medical heating blankets for clinical surgery and further certification expenses.
- Revenues EUR 23.9 million (2020: EUR 27.5 Million)
- EBITDA 2,304 kEUR (2020: 4,347 kEUR) • EBITDA-Margin 9.6% (2020: 15.8%)
- Operating profit (EBIT) 590 kEUR (without depreciation of medical heating blankets for clinical surgery: 1,517 kEUR) (2020: 3,097 kEUR)
- result from ordinary operations 308 kEUR (2020: 2,719 kEUR) • Earnings per share 2 cents (2020: 41 cents)
- Equity ratio 54.0% (2020: 55.4%) • Cash and securities EUR 6.5 million (2020: EUR 10.3 million)
- Proposed dividend: 12 cents per share (2020: 40 cents per share)
- Ongoing good international demand for Geratherm medical product
Geratherm Respiratory and apoplex medical had a good development in 2021. Sales split of the divisions Healthcare Diagnostic EUR 13.9 million, -24.3%; Respiratory EUR 5.6 million, +15.6%; Medical warming systems EUR 2.0 million, -18.5%; Cardio/Stroke 2.5 million EUR, +34.0%.
The detailed Annual Report 2021 will be published on April 26, 2022
Publication of insider information in accordance with Article 17 MAR, transmitted by DGAP - a service of EQS-Group AG
